In recent years, the development of both medical imaging and new systemic agents
(targeted therapy and immunotherapy) have revolutionized the field of oncology, leading to …

An increasing body of experience suggests that oligometastasis represents a minimal
metastatic state with the potential for cure or prolonged survival in selected patients treated …

Simple Summary The historical standard treatment of metastatic non-small cell lung cancer
(NSCLC) consisted of palliative chemotherapy, with limited influence on survival. With the …

The lung is the most common site of metastasis from various cancers, and an accurate
diagnosis of pulmonary oligometastasis is now possible with advances in diagnostic tools …

Oligometastasis is defined as the presence of several limited metastatic lesions and is
generally limited to three or fewer than five metastatic lesions. Previously, the treatment of …

The oligometastatic disease concept suggests that patients with a limited number of
metastases have a favorable prognosis. Radical local treatment of oligometastatic patients …

Patients with nonsmall cell lung cancer and limited metastatic disease have been defined as
oligometastatic if local ablative therapy of all lesions is amenable. Evidence from different …

Introduction Pulmonary oligometastases have conventionally been managed with surgery
and/or systemic therapy. However, given concerns about the high cost of systemic therapy …

Local treatment for pulmonary oligometastases (one to five lesions) using metastasectomy
or stereotactic ablative radiotherapy (SABR) was investigated in a cohort that received …

The so-called “Oligomez” trial was a randomized phase 2 trial for patients with
oligometastatic non-small cell lung carcinoma (NSCLC) performed at the MD Anderson …